Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features

The Fox Investigation of New Biomarker Discovery

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P =.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P <.01), and correlated weakly with MoCA recall scores (r = 0.23, P =.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P <.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps <.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalMovement Disorders
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

alpha-Synuclein
Saliva
Parkinson Disease
Cerebrospinal Fluid
Biomarkers
REM Sleep Behavior Disorder
Phenotype
Gait
Amyloid
Observational Studies
Cross-Sectional Studies

Keywords

  • alpha-synuclein
  • amyloid
  • cerebrospinal fluid
  • postural instability gait difficulty
  • tau

Cite this

Cerebrospinal fluid, plasma, and saliva in the BioFIND study : Relationships among biomarkers and Parkinson's disease Features. / The Fox Investigation of New Biomarker Discovery.

In: Movement Disorders, Vol. 33, No. 2, 01.02.2018, p. 282-288.

Research output: Contribution to journalArticle

@article{c3e77d9833a6428e89ff8787946266ca,
title = "Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features",
abstract = "Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P =.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P <.01), and correlated weakly with MoCA recall scores (r = 0.23, P =.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P <.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps <.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.",
keywords = "alpha-synuclein, amyloid, cerebrospinal fluid, postural instability gait difficulty, tau",
author = "{The Fox Investigation of New Biomarker Discovery} and Goldman, {Jennifer G.} and Howard Andrews and Amy Amara and Anna Naito and Alcalay, {Roy N.} and Shaw, {Leslie M.} and Peggy Taylor and Tao Xie and Paul Tuite and Claire Henchcliffe and Penelope Hogarth and Samuel Frank and Saint-Hilaire, {Marie Helene} and Mark Frasier and Vanessa Arnedo and Reimer, {Alyssa N.} and Margaret Sutherland and Christine Swanson-Fischer and Katrina Gwinn and Kang, {Un Jung}",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/mds.27232",
language = "English (US)",
volume = "33",
pages = "282--288",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Cerebrospinal fluid, plasma, and saliva in the BioFIND study

T2 - Relationships among biomarkers and Parkinson's disease Features

AU - The Fox Investigation of New Biomarker Discovery

AU - Goldman, Jennifer G.

AU - Andrews, Howard

AU - Amara, Amy

AU - Naito, Anna

AU - Alcalay, Roy N.

AU - Shaw, Leslie M.

AU - Taylor, Peggy

AU - Xie, Tao

AU - Tuite, Paul

AU - Henchcliffe, Claire

AU - Hogarth, Penelope

AU - Frank, Samuel

AU - Saint-Hilaire, Marie Helene

AU - Frasier, Mark

AU - Arnedo, Vanessa

AU - Reimer, Alyssa N.

AU - Sutherland, Margaret

AU - Swanson-Fischer, Christine

AU - Gwinn, Katrina

AU - Kang, Un Jung

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P =.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P <.01), and correlated weakly with MoCA recall scores (r = 0.23, P =.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P <.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps <.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.

AB - Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P =.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P <.01), and correlated weakly with MoCA recall scores (r = 0.23, P =.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P <.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps <.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.

KW - alpha-synuclein

KW - amyloid

KW - cerebrospinal fluid

KW - postural instability gait difficulty

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=85038265593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038265593&partnerID=8YFLogxK

U2 - 10.1002/mds.27232

DO - 10.1002/mds.27232

M3 - Article

C2 - 29205509

AN - SCOPUS:85038265593

VL - 33

SP - 282

EP - 288

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 2

ER -